Showing results (141-150 of 157) with videos related to
Sort By:
Pageof 16
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.Cancer Biology & Therapy|July 13, 2012
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentOlga Frolova, Ismael Samudio, Juliana Maria Benito, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaFarhad Ravandi, Jorge E Cortes, Daniel Jones, et al.Crohn'S & Colitis 360|March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseaseQuazim A Alayo, Marc Fenster, Osama Altayar, et al.Blood|August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterYasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.Pageof 16